Fraunhofer Institute for Toxicology and Experimental Medicine
Fraunhofer Institute for Toxicology and Experimental Medicine
Close-up of a pipette tip reaching into liquid on a slide.
Stationspartner Herr Alper, TOTAL Deutschland GMBH, TOTAL StationStarnberg, Münchnerstr.16, 82319 Starnberg

Therapy Response Identification through Low-input Omics

Improved therapy response prediction and more precise diagnostics for personalized medicine.

© Fraunhofer ITEM, Patrick Reinig

TRILO

As minimally invasive techniques such as liquid biopsy gain importance in disease assessment, technologies to analyze small sample amounts (“low-input”) become crucial. TRILO addresses this need by enabling comprehensive profiling of both genome and transcriptome of ultra-rare single cells or selectively enriched cell populations.

Its modular design ensures a seamless workflow, spanning from single cell isolation to high-precision data analysis. TRILO supports multiple applications including biomarker discovery and diagnostics for personalized medicine.

How does the TRILO Technology work?

Illustration of the TRILO technology
© Fraunhofer ITEM, Created with BioRender.com
Illustration of the TRILO technology

Our Service – Therapy Response Identification through Low-input Omics

© Fraunhofer ITEM, Ralf Mohr
A flow cell for high-throughput DNA sequencing with the Illumina MiSeq system.
  • GDPR-compliant access to patient samples through our extensive clinical network
    • Multiple cancer entities and sample types (incl. metastases, lymph nodes, blood)
    • Tailored patient recruitment to fulfill specific requirements (such as treatment resistance)
  • Advanced low-input genomics and transcriptomics methods (small cell populations down to single cells)
  • Comprehensive customized bioinformatic analysis
  • Biomarker discovery and validation

Your Benefits

  • Take advantage of our long-standing expertise in liquid biopsy and single cell analysis
  • Our established clinical network allows access to the right tissue samples for your studies
  • Plan fully modular and scalable R&D projects perfectly fitting to your needs
  • GDPR-compliant documentation, analysis and integration of molecular and clinical data by our in-house bioinformatics unit
  • We are eligible for international and national public funding initiatives

What does a typical TRILO project look like?

Expand all Close all

Study design

Collaboration directly from the start ensures an approach tailored to your needs.

With an experienced project manager by your side, you receive timely updates and clear communication throughout the project. Our experts guide you through sample selection, readouts and data analysis options.

Project initiation

We perform all regulatory steps to ensure GDPR-compliant patient sample and data handling while simultaneously finalizing preparations for your customized workflow of choice.

Proof-of-Concept Study

We recruit a small patient cohort to check, optimize, and adapt the assays and the study design.

Main Study

After the successful proof-of-concept study, we generate data from a large patient cohort. Our team provides constant updates on our progress. Once we have finalized our analyses, we provide you with a comprehensive report containing actionable insights.

Ongoing collaboration and follow-Up

We maintain open communication, can provide further analyses upon request and are happy to plan your next projects with you.

Sample projects

 

© Fraunhofer ITEM

Ex-vivo expansion of disseminated cancer cells is associated with progression of the disease in patients

Read More

Biomarker studies help optimize treatment for rare or hard-to-treat cancers

Read More

CSF diagnostics of brain tumors based on single tumor cells

Read more

Single-cell microRNA sequencing: Method comparison and application to cell lines and circulating lung tumor cells

Read more

Extending the liquid biopsy concept to brain tumor diagnosis

Read More

Relevant publications

Polzer B, Medoro G, Pasch S, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014;6(11):1371-1386. doi:10.15252/emmm.201404033

Werner-Klein M, Scheitler S, Hoffmann M, et al. Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun. 2018;9(1):595. Published 2018 Feb 9. doi:10.1038/s41467-017-02674-y

Weidele K, Stojanović N, Feliciello G, et al. Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples. Int J Cancer. 2019;145(1):232-241. doi:10.1002/ijc.32092

Franken A, Honisch E, Reinhardt F, et al. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. J Mol Diagn. 2020;22(1):111-121. doi:10.1016/j.jmoldx.2019.09.004

Hücker SM, Fehlmann T, Werno C, et al. Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells. Nat Commun. 2021;12(1):4316. Published 2021 Jul 14. doi:10.1038/s41467-021-24611-w